Interview with Willem Dekker , Regional Director, Nycomed Australia
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
Address: 2-4 Lyonpark Road,MACQUARIE PARK NSW 2113,Australia
Tel: 61 (02) 9859 6900
Web: http://www.takedaaustralia.com.au/au/
Building valued partnerships with the medical professionals who prescribe and recommend our products is both Nycomed Australia’s greatest challenge and our greatest reward. These aspirations as well as our commitment to provide medicines that offer real promise to patients, drives us to seek innovative and efficient ways of presenting our products to the Australian market.
Through a commitment to the ethical and professional delivery of quality medical education, Nycomed Australia is continually building valued relationships with the medical community. This is achieved by the creation of focused disease state education programs, and the facilitation of knowledge sharing between thought leaders and primary care practitioners. While Nycomed Australia always strive to keep Somac® (pantoprazole) and Alvesco ® (ciclesonide) at the ‘top of the mind’ of Australian prescribers, activities are often unrelated to their products and instead focus on topics of clearly identified educational needs within the areas of Gastroenterology and Respiratory Medicine.
In addition to building relationships with individual healthcare professionals, Nycomed Australia seeks to develop productive partnerships with the peak bodies that share our therapeutic focus. For example, The Gastroenterology Society of Australia guides us in the field of gastroenterology. In the area of respiratory medicine, Nycomed Australia has developed positive relationships with both the National Asthma Council and the Australian Lung Foundation. Nycomed Australia is also excited by the prospect of pioneering new relationships with peak bodies in emerging areas of therapeutic interest.
As a member of Medicines Australia, Nycomed Australia is devoted to strengthening the pharmaceutical industry’s position as a partner in quality healthcare delivery. This is achieved through the ethical promotion of our products and our support of the Medicines Australia code of conduct. Nycomed and its people are proud of their contribution to the Australian healthcare environment and seek to ensure that their organisation acts as a trusted pharmaceutical partner.
Every day across Australia, our highly trained industry-accredited representatives bring life to our products and services. They are the face of Nycomed Australia.
Nycomed Australia’s professional team is committed to our vision to become the preferred pharmaceutical company by being responsive, reliable and by understanding customer needs.
Gastroenterology and Respiratory Medicine
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
New Government health priorities and policies, highlighting those concerning preventive health. The Rudd Labor Government’s goal in health is to create a modern health system designed for the health needs…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare…
Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee (PBAC) is a statutory committee of the Australian government which…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
What impact will the recent PBS reforms have on Stiefel’s operations in Australia? Stiefel has no products on the PBS at the moment, and although that doesn’t preclude the company…
Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines…
To begin, would you please give a brief introduction to the PBAC? The PBAC is a statutory committee of government first developed in Australia in the 1940s, which advises the…
The Ministry for Innovation, Industry, Science and Research was created in December 2007 with the election of the Labor government. To begin, would you please give a brief introduction to…
See our Cookie Privacy Policy Here
